Talzenna .75 mg/1

Talzenna .75 mg capsules are a pharmaceutical product used in cancer treatment. This medication contains talazoparib, a PARP inhibitor, and is manufactured by Pfizer Laboratories.

Talzenna .75 mg capsules are primarily used in the treatment of certain types of cancer. Talazoparib, the active ingredient, is a PARP inhibitor that works by targeting specific enzymes involved in DNA repair. This medication is often prescribed for patients with specific genetic mutations, such as BRCA mutations, which are commonly associated with breast and ovarian cancers. The use of Talazoparib can help in slowing the growth of cancer cells and improving patient outcomes.

Common effects of Talzenna .75 mg capsules may include fatigue, nausea, and anemia. Some patients may also experience vomiting, decreased appetite, and hair loss. These effects can vary in severity and may not affect everyone who takes the medication. It is important to consult with a healthcare provider for personalized advice on managing these effects.

When handling Talzenna .75 mg capsules, it is important to follow the prescribed dosage and administration instructions. This medication should be stored at room temperature and kept out of reach of children. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions. Pregnant women or those planning to become pregnant should discuss the risks and benefits with their healthcare provider.

Talzenna .75 mg capsules may interact with certain medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol consumption should be avoided while taking this medication, as it may increase the risk of side effects. Always consult with a healthcare provider for personalized advice on managing potential interactions.